SEO URLwww.firestrike.ai/deals/avidity-biosciences-novartis-acquisition-2026-1
acquisitionAnnounced · Mar 16, 2026pharmaceuticalSource · CredibleArticle · Factual
Novartis acquires Avidity Biosciences
David Najork · Founding Software Engineer
Published · Updated · 1 min read
Deal value
$12B
Target
Avidity Biosciences
NASDAQ: RNA · San Diego, California
Acquirer
Novartis
Full Acquisition
Status
Completed
Novartis agreed to acquire Avidity Biosciences. Reported deal value: $12B. Status: Completed. Sector: pharmaceutical. Target headquarters context: San Diego, California, United States.
This page summarizes publicly available information about the transaction as of 2026-03-16. Figures and status may change as filings and press coverage update.
By Kelly Cloonan Novartis is issuing debt offerings to help fund its $ 12 billion acquisition of Avidity Biosciences
Deal timeline
Announced
Mar 16, 2026 · marketscreener.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in pharmaceutical with a reported deal value of $12B. Figures and status may change as sources update.
Sources: marketscreener.com · Primary article · FireStrike proprietary index